ISG posts healthy quarter, inks Philips deal
ISG Technologies recorded healthy gains in revenue during its first quarter, which is traditionally the software developer’s weakest revenue-generating period. Revenue grew 10%, while net income also climbed during the quarter (end-September).For
ISG Technologies recorded healthy gains in revenue during its first quarter, which is traditionally the software developers weakest revenue-generating period. Revenue grew 10%, while net income also climbed during the quarter (end-September).
For the period, the Mississauga, Ontario-based firm reported revenue of $5.8 million (U.S.), compared with $5.3 million last year. Net income grew to $187,000, compared with $5800 in 1997.
In other ISG news, the company has signed a 10-year software development agreement with Philips Medical Systems. ISG will supply the Shelton, CT-based company with various medical imaging products and custom engineering services. Specifically, ISG will continue to develop image viewing, image processing, and filming software for the primary console for the modality vendors Gyroscan NT MRI scanner. It will also provide ISG services for other Philips medical products in the future.
Philips, which has maintained a supply relationship with ISG since 1988, also recently signed an agreement to join the Surgical Navigation Network, a consortium of companies working to integrate image-guided surgery technology products. SNN companies have agreed to use the Windows NT-based image-guided surgery software system produced by Surgical Navigation Specialists, a joint venture between ISG and Carl Zeiss (SCAN 9/16/98).
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
